Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Neurogene (NGNE) EBIT: 2018-2025

Historic EBIT for Neurogene (NGNE) over the last 4 years, with Sep 2025 value amounting to -$23.8 million.

  • Neurogene's EBIT fell 7.29% to -$23.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$97.3 million, marking a year-over-year decrease of 28.33%. This contributed to the annual value of -$82.6 million for FY2024, which is 48.62% down from last year.
  • Per Neurogene's latest filing, its EBIT stood at -$23.8 million for Q3 2025, which was up 8.75% from -$26.1 million recorded in Q2 2025.
  • Over the past 5 years, Neurogene's EBIT peaked at -$12.6 million during Q2 2023, and registered a low of -$26.1 million during Q2 2025.
  • Its 3-year average for EBIT is -$19.5 million, with a median of -$20.1 million in 2024.
  • Data for Neurogene's EBIT shows a maximum YoY tumbled of 59.84% (in 2024) over the last 5 years.
  • Quarterly analysis of 3 years shows Neurogene's EBIT stood at -$14.7 million in 2023, then slumped by 46.01% to -$21.5 million in 2024, then dropped by 7.29% to -$23.8 million in 2025.
  • Its EBIT was -$23.8 million in Q3 2025, compared to -$26.1 million in Q2 2025 and -$25.9 million in Q1 2025.